Cancer NetworkOriginal article
<![CDATA[How Effective is Fixed-Duration Cevostamab in Multiple Myeloma?]]>
Phase 1positivecevostamabPositive
AI Analysis
Summary
Phase 1 trial data for cevostamab in multiple myeloma demonstrated that fixed-duration therapy is a viable therapeutic approach, according to clinical commentary from Adam D. Cohen, MD.
Clinical Trial Data
Phase
1
Outcome Details
Fixed-duration therapy validated as a good concept
Importance:5/10
Sentiment:
0.60
Phase 1multiple myelomacevostamabfixed-duration therapy
Read the original article
Published by Cancer Network on August 4, 2026 12:00 PM